Neurology

Real-world CIDP treatment is highly heterogeneous; IVIg/SCIg use increased over 2015–2025

Multicentre registry of 653 CIDP patients across 24 Italian tertiary centres profiled induction and maintenance treatments from 2015–2025. Use of IVIg and SCIg increased over time while corticosteroids, plasma exchange, and traditional immunosuppressants declined. Centre-level organisational factors, local prescribing culture, patient preference, and treatment period independently influenced therapy choice. Lower IVIg induction doses and use of oral corticosteroids were associated with worse long-term outcomes, supporting standardised, evidence-based treatment pathways. 1

People with MS show moderate, domain-specific acceptance of AI; prefer shared clinician responsibility

Survey of 241 people with MS found moderate overall AI acceptance (mean 3.39, SD 0.78) with higher comfort for management and screening than diagnosis or treatment selection. Frequent general AI use and geographic region predicted higher acceptance; disability did not, and older age predicted lower acceptance. Assuming equal accuracy, 78.8% preferred joint AI-clinician decisions with clinician final responsibility. Authors recommend phased, transparent, clinician-led ‘human-in-the-loop’ adoption starting with low-risk applications. 2

Lifestyle interventions show mixed but potentially meaningful seizure reduction and QoL benefits

Systematic review of 118 studies (n=5151 screened) found pooled ≥50% seizure reduction rates of 44% short-term and 50% long-term. Dietary interventions had the largest evidence base (n=33) with ~40% short-term and 51% long-term response rates; meditation/yoga showed higher response rates. Quality of life improved in about 68% of studies that measured it. Heterogeneity and variable study quality limit certainty; larger standardized trials are needed before broad clinical endorsement. 3